Dwayne Hoover
Footballguy
I know, almost as good as the news itselfImagine being short on this over the weekend. Merry Christmas lol
I know, almost as good as the news itselfImagine being short on this over the weekend. Merry Christmas lol
Bahhhhh Humbug! What?My big concern is the statement that the results of the phase 2 trial will not support Eind.
Read up. Probably not eligible since they wouldn’t need it on an emergency basis.I might actually make some money on this thing!! Merry Christmas to all!
Not sure what you guys were expecting but if Leron gets approval for severe critical it is a huge win. I literally had 0 expectations for anything mild to moderate but at this point this story is still evolving, not gonna say its game over everywhere either.Read up. Probably not eligible since they wouldn’t need it on an emergency basis.
I read it that CD12 type patients can get the drug which is a good thing.Read up. Probably not eligible since they wouldn’t need it on an emergency basis.
I'd like to hear a solid counter argument why it wouldn't be (not the CD10 part, i don't care about that)With “Stacey’s Mom” playing in the background, I am quietly hopeful that the market will interpret this news as it is—very positive.
Monday should be good!!!
Well at least when he crashes it into your car and dents it, you;ll know a good attorney to sue him and the manufacturer.one of those toddler-sized cars he can drive around in. Came with no instructions (a-holes) so I had to wing it. Probably will end up only having 3 working wheels and the radio will pick up the BBC or something. .
- Nasdaq uplift in 4-6 weeks.I'd like to hear a solid counter argument why it wouldn't be (not the CD10 part, i don't care about that)
Yeah, not buying any of this. They aren't playing games at this point and I've been as critical of NP as any.- Nasdaq uplift in 4-6 weeks.
- HIV BLA near
- Submitting for EUA
The argument would be that CYDY rarely releases accurate information
Exactly.“Don’t shoot the messenger” but when I was invested I ended up seeking out / finding those who weren’t believers to figure out the bear case at the time. Their take(s):
https://twitter.com/kgromax/status/1342505317482033152?s=21
https://twitter.com/busttfraud/status/1342463357782290435?s=21
https://twitter.com/stanphylcap/status/1342186271825911808?s=21
https://twitter.com/googlepumpdump/status/1342322656977313793?s=21
There are long and shorts on Twitter speaking to their self-interests and spinning PRs like that every day. The market will make up its mind on Monday.“Don’t shoot the messenger” but when I was invested I ended up seeking out / finding those who weren’t believers to figure out the bear case at the time. Their take(s):
https://twitter.com/kgromax/status/1342505317482033152?s=21
https://twitter.com/busttfraud/status/1342463357782290435?s=21
https://twitter.com/stanphylcap/status/1342186271825911808?s=21
https://twitter.com/googlepumpdump/status/1342322656977313793?s=21
The shorts lose all credibility when they say the CD10 trial failed.“Don’t shoot the messenger” but when I was invested I ended up seeking out / finding those who weren’t believers to figure out the bear case at the time. Their take(s):
https://twitter.com/kgromax/status/1342505317482033152?s=21
https://twitter.com/busttfraud/status/1342463357782290435?s=21
https://twitter.com/stanphylcap/status/1342186271825911808?s=21
https://twitter.com/googlepumpdump/status/1342322656977313793?s=21
Why does the data not support an eIND request then? No idea how this stuff actually works, but doesn’t seem...good...that this line is in there?The shorts lose all credibility when they say the CD10 trial failed.
eIND is for emergency use. Moderate is for moderate. Shouldn’t have been included though, I agree.Why does the data not support an eIND request then? No idea how this stuff actually works, but doesn’t seem...good...that this line is in there?
kgromax, busttfraud and googlepumpdump are virtually unreadable. They spend every day of the week bashing Cytodyn, like all day long. I stopped paying attention to them a long time ago.“Don’t shoot the messenger” but when I was invested I ended up seeking out / finding those who weren’t believers to figure out the bear case at the time. Their take(s):
https://twitter.com/kgromax/status/1342505317482033152?s=21
https://twitter.com/busttfraud/status/1342463357782290435?s=21
https://twitter.com/stanphylcap/status/1342186271825911808?s=21
https://twitter.com/googlepumpdump/status/1342322656977313793?s=21
They seem to be getting slotted for severe critical, at least in the USA. I don't really see an issue here.Why does the data not support an eIND request then? No idea how this stuff actually works, but doesn’t seem...good...that this line is in there?
They definitely failed the primary endpoint. Whether they found something with the News2 to perhaps pursue a phase 3 was possible but they never moved on it. Not sure if that was because of how late in the game it would be to start another trial or if they thought it would be a longer shot to get approval for mild to moderate. Probably a little bit of both really.The shorts lose all credibility when they say the CD10 trial failed.
Phase 2 trials are about figuring out what to target for the phase 3 trial. Hitting any kind of endpoint with statistical significance is the goal so that a phase 3 study can ensue. Shorts continually claiming the phase 2 failed show that they're not objective and as such, I don't believe their other claims.They definitely failed the primary endpoint. Whether they found something with the News2 to perhaps pursue a phase 3 was possible but they never moved on it. Not sure if that was because of how late in the game it would be to start another trial or if they thought it would be a longer shot to get approval for mild to moderate. Probably a little bit of both really.
At this point, severe critical is good enough to validate them and is where I'm focused.
I dont disagree and those twitter handles that @eaganwildcats linked are really the worst of the worst. It's not even worth spending any time on them.Phase 2 trials are about figuring out what to target for the phase 3 trial. Hitting any kind of endpoint with statistical significance is the goal so that a phase 3 study can ensue. Shorts continually claiming the phase 2 failed show that they're not objective and as such, I don't believe their other claims.
It didn’t meet its primary goal in a statistical significant mannerThe shorts lose all credibility when they say the CD10 trial failed.
It didn’t meet its primary goal in a statistical significant manner
Phase 2 trials are about figuring out what to target for the phase 3 trial. Hitting any kind of endpoint with statistical significance is the goal so that a phase 3 study can ensue. Shorts continually claiming the phase 2 failed show that they're not objective and as such, I don't believe their other claims.
That it was a failureHas all of the data been released from the M2M trial? If not, what are they hiding?
The M2M data is the only data from a double blind study that exists. CytoDyn saying it is great data while keeping it secret is dubious. We have no idea if the S/C data are good since the trial is still blinded. All we know is that the data from the S/C trial wasn't so horrible or so amazing to warrant stopping the trial early. But people who insist that the S/C is going to be incredible can only point to the M2M trial and the EINDs as proof. Neither the M2M trial or the EINDs are reliable evidence.Why are we talking about Cd 10? Completely irrelevant right now, the market couldn’t care less.
All I care about is the stock price. CD 10 has already been factored in, bottom line. The future price will rise or sink based on the next set of results. 10 is completely irrelevant now except for meaningless bickering online.The M2M data is the only data from a double blind study that exists. CytoDyn saying it is great data while keeping it secret is dubious. We have no idea if the S/C data are good since the trial is still blinded. All we know is that the data from the S/C trial wasn't so horrible or so amazing to warrant stopping the trial early. But people who insist that the S/C is going to be incredible can only point to the M2M trial and the EINDs as proof. Neither the M2M trial or the EINDs are reliable evidence.
Maybe so, but as we have seen before this attack will probably tank this thing on Monday. Releasing that press release on Christmas Eve just seems like some weak sauce to me.All I care about is the stock price. CD 10 has already been factored in, bottom line. The future price will rise or sink based on the next set of results. 10 is completely irrelevant now except for meaningless bickering online.
Yea there are parts of the release I didn’t like, but my point about CD10 now being irrelevant still stands.Maybe so, but as we have seen before this attack will probably tank this thing on Monday. Releasing that press release on Christmas Eve just seems like some weak sauce to me.
You keep going back to this. I think Cytodyn essentially said the data wasn't that great when they didn't even apply for EUA or pursue a phase 3. Let's stop talking about CD10. it doesn't matter.The M2M data is the only data from a double blind study that exists. CytoDyn saying it is great data while keeping it secret is dubious. We have no idea if the S/C data are good since the trial is still blinded. All we know is that the data from the S/C trial wasn't so horrible or so amazing to warrant stopping the trial early. But people who insist that the S/C is going to be incredible can only point to the M2M trial and the EINDs as proof. Neither the M2M trial or the EINDs are reliable evidence.
I have the results. 2500 page document.Has all of the data been released from the M2M trial? If not, what are they hiding?
Please post it inI have the results. 2500 page document.
She ended up recovering.Meanwhile, Baluyot was deteriorating. She was transferred to Regional Medical Hospital in San Jose on March 9, where she was placed on a life support machine to preserve her heart and lung function.
While she was on life support, Baluyot received the antiviral medicine remdesivir and leronlimab, a therapy for severe and critical COVID patients that was used under the FDA’s emergency new drug program.
I pointed out to Kgromax that they said the same thing about overstock and then that account blocked mekgromax, busttfraud and googlepumpdump are virtually unreadable. They spend every day of the week bashing Cytodyn, like all day long. I stopped paying attention to them a long time ago.
Not sure about stanphylcap, that's one I don't know, but I don't see anything interesting
No advisors for a publicly-traded company would recommend a major press release on Christmas Eve. Why did CytoDyn make this announcement when it did? To save lives, hours, and days matter.
lol I don’t know about that one.
I would have to get all new underwear if this thing goes to $12.
$12 would be a $7.2B market cap. HGEN at $22 is a $1.1B market cap.I would have to get all new underwear if this thing goes to $12.
Well you’ll certainly be able to afford it.I would have to get all new underwear if this thing goes to $12.
The market does not care about rational thought. It’s all froth. You know this. If you want to apply these principles to your trading that’s fine but it’s kind of antiquated thinking for what’s been going on the last 9 months.$12 would be a $7.2B market cap. HGEN at $22 is a $1.1B market cap.
Maybe it gets there but market cap wise, even $10 is stretching it with the vaccines and honestly a lot more cancer drugs/companies making strides there. The competitive landscape is way different now than it was back in late June.
If I still had any, I’d put my limit order in for $9 like I should have back in June.
Acting like fundamentals are antiquated thinking is how you miss selling in the froth before the market corrects. There is no “new” world order. Stocks aren’t going to all of a sudden always be worth twice as much in the future. That’s why I threw out my thoughts that I’d look at the June peak as a good out. Maybe it’s not the top but it’s extremely hard to time it and we already saw how fast the table can turn and June was a far different competitive landscape than today. Feel free to do whatever you want just my thoughts. I just remember saying I’d be happy with $9 a share buyout and getting chastised because it could go to $20. I should have listened to myself, would have made me twice as much.The market does not cate about rational thought. It’s all froth. You know this. If you want to apply these principles to your trading that’s fine but it’s kind of antiquated thinking for what’s been going on the last 9 months.